GlassScriptPhysician profile
Amy Sugar
NPI 1891210944
$9,184.20
in general payments reported to CMS, 2019-2025
36 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $2,879 · 2023: $2,286 · 2024: $1,787 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,697 · Education: $98.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,697.33 |
| Education | $98.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,386.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,004.77 | 2022-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $806.72 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $500.41 | 2023-2025 | Voquezna |
| Genzyme Corporation | $405.50 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $396.09 | 2022-2024 | Ocaliva |
| Evoke Pharma, INC. | $348.67 | 2022-2024 | Gimoti |
| Janssen Biotech, INC. | $316.72 | 2021-2025 | Stelara, Tremfya, Remicade |
| Lilly USA, LLC | $305.32 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $292.78 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $213.71 | 2021-2025 | Wegovy, Ozempic |
| Ferring Pharmaceuticals INC. | $208.91 | 2021-2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $188.13 | 2022-2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $177.82 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $158.71 | 2024-2025 | Iqirvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $139.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $131.55 | 2022-2025 | Amjevita, Uplizna |
| Celgene Corporation | $129.47 | 2022-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $122.55 | 2023 | Xarelto |
| Ironwood Pharmaceuticals, INC | $115.22 | 2022-2025 | Linzess |
| Abbott Laboratories | $108.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.05 | 2022 | |
| Pfizer INC. | $98.04 | 2025 | |
| Qol Medical, LLC | $91.85 | 2022-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $85.38 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $73.73 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $53.00 | 2023-2024 | Suflave, Sutab |
| Gilead Sciences, INC. | $36.36 | 2024 | |
| Fresenius Kabi USA, LLC | $33.58 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $29.22 | 2022-2023 | Injectafer |
| Redhill Biopharma INC. | $26.90 | 2022 | |
| Mylan Institutional INC. | $26.73 | 2023 | |
| Ethicon US, LLC | $22.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.08 | 2024 | Cyltezo |
| Celltrion USA INC. | $14.15 | 2024 | Zymfentra |
| Organon LLC | $11.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.